{"DataElement":{"publicId":"6618094","version":"1","preferredName":"Prostate Carcinoma Risk Factor Assessment Stage Grouping NCCN Category","preferredDefinition":"Text term used to describe the gathering of information regarding the variables associated with an individual's increased risk of getting prostate cancer as outlined by the NCCN guidelines.","longName":"PRS_CA_RSK_FAC_ASSES_CAT","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6618089","version":"1","preferredName":"Prostate Carcinoma Risk Factor Assessment Stage Grouping","preferredDefinition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_A systematic gathering of information regarding the variables associated with an individual's increased risk of disease or infection._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"2744055v1.0:6618472v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"2744055","version":"1","preferredName":"Prostate Carcinoma","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002","longName":"C4863","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B8AEEC8-FDF2-03F8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-23","modifiedBy":"ONEDATA","dateModified":"2008-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6618472","version":"1","preferredName":"Risk Factor Assessment Stage Grouping","preferredDefinition":"A systematic gathering of information regarding the variables associated with an individual's increased risk of disease or infection.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","longName":"C90498:C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risk Factor Assessment","conceptCode":"C90498","definition":"A systematic gathering of information regarding the variables associated with an individual's increased risk of disease or infection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8023FFF4-A5E9-748F-E053-F662850A8934","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8021D09B-7421-3553-E053-F662850AB94E","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeDescription":"1/23/19 ls  CDE to capture NCCN guidelines Version 3.2018 Prostate Cancer Risk Groups.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6618091","version":"1","preferredName":"NCCN Stage Grouping Category","preferredDefinition":"The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable._Any number of entities (members) considered as a unit._A grouping of items based on some commonality or by user defined characteristics._An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancersA grouping of items based on some commonality or by user defined characteristics.","longName":"6618091v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Metastatic","valueDescription":"Metastatic","ValueMeaning":{"publicId":"5189148","version":"1","preferredName":"Metastatic","longName":"5189148","preferredDefinition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metastatic","conceptCode":"C14174","definition":"A term referring to the clinical or pathologic observation of a tumor extension from its original site of growth to another anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E972B2B-1743-F356-E050-BB89AD4360B6","latestVersionIndicator":"Yes","beginDate":"2016-03-21","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2016-03-21","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"802B9F1F-2D68-6E31-E053-F662850A3D26","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Regional","valueDescription":"Regional","ValueMeaning":{"publicId":"2565856","version":"1","preferredName":"Regional","longName":"2565856","preferredDefinition":"Of or belonging to a broader area or region of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Regional","conceptCode":"C25643","definition":"Of or belonging to a broader area or region of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CE4D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-04-11","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-04-11","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"802B9F1F-2D73-6E31-E053-F662850A3D26","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Unfavorable Intermediate","valueDescription":"Unfavorable Intermediate Risk","ValueMeaning":{"publicId":"6618457","version":"1","preferredName":"Unfavorable Intermediate Risk","longName":"6618457","preferredDefinition":"Expressing something as negative, undesired or adverse.: The potential future harm that may arise from some present action or attribute or condition is moderate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unfavorable","conceptCode":"C102561","definition":"Expressing something as negative, undesired or adverse.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intermediate Risk","conceptCode":"C102402","definition":"The potential future harm that may arise from some present action or attribute or condition is moderate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"80257B9A-D15B-3895-E053-F662850AE09D","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"SOKKERL","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80257B9A-D174-3895-E053-F662850AE09D","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Favorable Intermediate","valueDescription":"Favorable Intermediate Risk","ValueMeaning":{"publicId":"6618458","version":"1","preferredName":"Favorable Intermediate Risk","longName":"6618458","preferredDefinition":"Expressing something as positive, advantageous or desired.: The potential future harm that may arise from some present action or attribute or condition is moderate.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Favorable","conceptCode":"C102560","definition":"Expressing something as positive, advantageous or desired.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intermediate Risk","conceptCode":"C102402","definition":"The potential future harm that may arise from some present action or attribute or condition is moderate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"80257B9A-D181-3895-E053-F662850AE09D","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"SOKKERL","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80257B9A-D19A-3895-E053-F662850AE09D","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Low","valueDescription":"Low Risk","ValueMeaning":{"publicId":"2762643","version":"1","preferredName":"Low Risk","longName":"2762643","preferredDefinition":"The potential future harm that may arise from some present action or attribute or condition is small.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Risk","conceptCode":"C102403","definition":"The potential future harm that may arise from some present action or attribute or condition is small.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"510F60C2-8B40-00A5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-02","modifiedBy":"SOKKERL","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8025429E-AC16-748B-E053-F662850A6B3A","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"High","valueDescription":"High Risk","ValueMeaning":{"publicId":"2762642","version":"1","preferredName":"High Risk","longName":"2762642","preferredDefinition":"The potential future harm that may arise from some present action or attribute or condition is almost certain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"High Risk","conceptCode":"C102401","definition":"The potential future harm that may arise from some present action or attribute or condition is almost certain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"510F69B8-A6A8-0143-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-07-02","modifiedBy":"HARTLEYG","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8025429E-AC2A-748B-E053-F662850A6B3A","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Very Low","valueDescription":"Very Low Risk","ValueMeaning":{"publicId":"6618455","version":"1","preferredName":"Very Low Risk","longName":"6618455","preferredDefinition":"Existing to a great degree.: The potential future harm that may arise from some present action or attribute or condition is small.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Very","conceptCode":"C116076","definition":"Existing to a great degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Low Risk","conceptCode":"C102403","definition":"The potential future harm that may arise from some present action or attribute or condition is small.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"80256515-CEE7-20CF-E053-F662850AAA77","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80256515-CF00-20CF-E053-F662850AAA77","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"Very High","valueDescription":"Very High Risk","ValueMeaning":{"publicId":"6618456","version":"1","preferredName":"Very High Risk","longName":"6618456","preferredDefinition":"Existing to a great degree.: The potential future harm that may arise from some present action or attribute or condition is almost certain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Very","conceptCode":"C116076","definition":"Existing to a great degree.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"High Risk","conceptCode":"C102401","definition":"The potential future harm that may arise from some present action or attribute or condition is almost certain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"80256515-CF0D-20CF-E053-F662850AAA77","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80256515-CF26-20CF-E053-F662850AAA77","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6618477","version":"1","preferredName":"National Comprehensive Cancer Network Stage Grouping Category","preferredDefinition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C39471:C38027:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Comprehensive Cancer Network","conceptCode":"C39471","definition":"An alliance of 19 leading US cancer centers, an authoritative source of information to help patients and health professionals make informed decisions about cancer care. Through the collective expertise of its member institutions, the NCCN develops, updates, and disseminates a complete library of clinical practice guidelines. These guidelines are the standard for clinical policy in oncology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"80260DD0-3CCD-3915-E053-F662850A74D0","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"80220802-5256-6E52-E053-F662850A362A","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"SOKKERL","dateModified":"2019-01-24","changeDescription":"CDE to capture NCCN guidelines Version 3.2018 Prostate Cancer Risk Groups. VD can not be extended for other values. 1/23/19.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"RS_RSORRES_RISKLVL","type":"OID, CCTG","context":"CCTG"}],"ReferenceDocuments":[{"name":"Theradex","type":"COMMENT","description":"CDE to capture NCCN guidelines Version 3.2018 Prostate Cancer Risk Groups.","url":null,"context":"Theradex"},{"name":"Risk Group","type":"Preferred Question Text","description":"Risk Group","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"80221FCC-AE36-6E69-E053-F662850A1ADA","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-01-23","modifiedBy":"CLOHNES","dateModified":"2023-11-16","changeDescription":"CDE to capture NCCN guidelines Version 3.2018 Prostate Cancer Risk Groups. 1/23/19 ls","administrativeNotes":"11/16/23 Added alt OID for CCTG ticket number CADSR0003085 cjl","unresolvedIssues":null,"deletedIndicator":"No"}}